Last updated: September 17, 2026
RELEXXII is a once-daily, extended-release oral suspension containing methylphenidate hydrochloride. Its commercial differentiation comes from liquid dosing, extended exposure, pediatric usability, and avoidance of tablet or capsule swallowing. The main excipient opportunities are improved taste, lower sedimentation risk, dosing accuracy, preservative optimization, and more convenient packaging. The principal competitive risks come from Quillivant XR, Dyanavel XR, extended-release tablets and capsules, and future generic liquid methylphenidate products.
What is RELEXXII and how does its formulation create commercial value?
RELEXXII is methylphenidate hydrochloride extended-release oral suspension, a Schedule II central nervous system stimulant approved for attention deficit hyperactivity disorder. The product is supplied as a ready-to-use liquid suspension rather than a powder requiring reconstitution. The FDA-approved concentration is 5 mg/mL, with a labeled dose range of 20 mg to 60 mg once daily in pediatric and adult patients, subject to titration and clinical judgment. Administration occurs approximately 45 minutes before breakfast. [1]
The formulation addresses several limitations of solid oral dosage forms:
- It supports children who cannot swallow tablets or capsules.
- It permits dose titration in 5 mg increments.
- It provides once-daily extended exposure.
- It avoids reconstitution at the pharmacy or caregiver level.
- It allows caregivers to adjust the dose without splitting tablets.
The commercial tradeoff is that liquid suspensions require a reliable dosing device, consistent redispersion, physical stability, acceptable taste, and protection against microbial contamination.
What excipients are important in RELEXXII?
The FDA prescribing information identifies a liquid suspension system containing excipients used for viscosity control, taste, pH management, preservation, and physical stability. Public labeling identifies components including glycerin, citric acid, sodium citrate, sucralose, xanthan gum, polysorbate 80, sodium benzoate, and water. [1,2]
| Excipient function |
Likely formulation role |
Commercial relevance |
| Xanthan gum or comparable polymer |
Suspension viscosity and particle control |
Supports dose uniformity but can increase pour resistance |
| Polysorbate 80 |
Wetting and dispersion |
Helps maintain uniform distribution of drug particles |
| Sodium benzoate |
Preservative |
Supports multidose packaging and in-use stability |
| Citric acid and sodium citrate |
Buffer system and pH control |
Affects taste, preservative performance, and methylphenidate stability |
| Sucralose |
Sweetener |
Reduces bitterness but may not fully mask stimulant taste |
| Glycerin |
Humectant, solvent, and mouthfeel modifier |
Can improve texture but may increase sweetness and viscosity |
The value of the excipient system is not created by any individual ingredient. It comes from the interaction between particle size, polymer concentration, pH, preservative system, wetting agent, flavor profile, and dosing device.
What excipient strategies could improve RELEXXII?
Can taste masking create a stronger pediatric product?
Yes. Taste is a direct adherence variable for chronic pediatric ADHD treatment. Methylphenidate can produce bitter or medicinal notes, and sweetener alone may not provide sufficient masking.
Potential strategies include:
- Flavor redesign. Fruit flavors, citrus systems, and layered flavor profiles can reduce bitterness and aftertaste.
- Polymer-based taste masking. Coating or complexing drug particles can delay dissolution in the mouth while preserving release in the gastrointestinal tract.
- Ion-exchange resin complexes. These can reduce immediate drug release and improve palatability, although they add manufacturing and regulatory complexity.
- Sweetener optimization. Sucralose can be combined with acesulfame potassium, stevia derivatives, or sugar alcohols, subject to pediatric tolerability and gastrointestinal considerations.
- Mouthfeel control. Excessive gum or glycerin can create a thick or sticky sensation. Lower-viscosity systems may improve acceptance without sacrificing suspension performance.
A reformulated product would need to maintain equivalent dose uniformity, dissolution, pharmacokinetic performance, microbial quality, and stability.
Can the suspension be made easier to shake and measure?
Yes. Suspension performance is a high-value improvement area. Caregivers may under-shake a product, resulting in nonuniform concentration between the first and last doses. An improved system could use:
- Smaller and more uniform drug particles.
- A lower-density particle population that reduces sedimentation.
- Controlled flocculation to prevent hard cake formation.
- Optimized xanthan gum or cellulose polymer levels.
- Bottle geometry that improves mixing.
- A calibrated oral syringe with low-resistance withdrawal.
- A visual resuspension indicator on the label or packaging.
The most commercially useful formulation would combine rapid redispersion with low viscosity. A product that requires vigorous shaking but has high pour resistance creates usability problems even if laboratory dose uniformity is acceptable.
Is preservative reduction a commercial opportunity?
Potentially. Sodium benzoate supports multidose product protection, but preservative systems can raise pediatric tolerability and formulation-positioning questions. A lower-preservative or preservative-free configuration could support premium positioning if it maintains microbiological quality through:
- Unit-dose sachets or cups.
- Smaller multidose bottles.
- Metered-dose dispensing systems.
- Airless or closed-container packaging.
- Aseptic manufacturing.
- Improved container-closure systems.
The principal limitation is cost. Unit-dose or closed-system packaging can increase manufacturing expense, packaging waste, and pharmacy handling requirements.
What patent and regulatory rights protect RELEXXII?
RELEXXII is a small-molecule product. It does not receive biosimilar protection, and biosimilar competition is not the relevant regulatory threat. Competition would generally arise through an abbreviated new drug application, a Paragraph IV certification, a 505(b)(2) application, or an authorized generic arrangement.
What is the Orange Book status of RELEXXII?
The FDA Orange Book is the controlling source for current listed patents, exclusivity, therapeutic-equivalence evaluations, and patent certifications. RELEXXII should be assessed using the product’s exact FDA application number and current Orange Book entries rather than relying on secondary patent databases. [3]
The relevant protection categories are:
- Drug substance patents: protection for methylphenidate compositions or particle forms.
- Drug product patents: protection for the extended-release suspension.
- Formulation patents: protection for excipient combinations, particle engineering, pH, viscosity, or suspension stability.
- Method-of-use patents: protection for dosing regimens, patient populations, or administration timing.
- Device or packaging patents: protection for dosing dispensers or container systems.
The strength of a formulation patent depends on claim scope and design-around difficulty. A claim directed to a broad class of excipients is easier to challenge or avoid than a claim requiring a narrow combination of polymer concentration, particle size, dissolution profile, and pharmacokinetic parameters.
When does RELEXXII lose exclusivity?
FDA marketing exclusivity and patent exclusivity are separate. Patent expiry depends on the Orange Book-listed patents, terminal disclaimers, patent-term adjustment, patent-term extension, and litigation outcomes. FDA exclusivity depends on the approval history and any applicable clinical or pediatric exclusivity.
A generic applicant may file an ANDA before patent expiry and certify that listed patents are invalid, unenforceable, or not infringed. A Paragraph IV notice can trigger a 30-month stay of FDA approval if the patent holder files infringement litigation within the statutory period. [4]
A product-specific launch forecast therefore requires:
| Issue |
Commercial effect |
| Listed formulation patent |
May delay or complicate generic approval |
| Method-of-use patent |
May permit label carve-outs but usually does not block all product competition |
| Patent litigation |
Can delay launch or create settlement-based entry dates |
| Pediatric exclusivity |
Can extend the effective regulatory barrier |
| Non-listed formulation know-how |
May remain a manufacturing barrier without blocking approval |
| Device dependence |
Can require a separate dispenser strategy for generic entry |
Which companies compete with RELEXXII?
How does RELEXXII compare with Quillivant XR and Dyanavel XR?
| Product |
Active ingredient |
Dosage form |
Release profile |
Primary differentiation |
| RELEXXII |
Methylphenidate hydrochloride |
Extended-release suspension |
Once daily |
Ready-to-use liquid methylphenidate |
| Quillivant XR |
Methylphenidate hydrochloride |
Extended-release suspension |
Once daily |
Established liquid methylphenidate brand |
| Dyanavel XR |
Amphetamine-based active ingredient |
Extended-release oral suspension |
Once daily |
Liquid amphetamine option |
| Concerta and generic equivalents |
Methylphenidate hydrochloride |
Extended-release tablet |
Once daily |
Established solid-dose delivery |
| QuilliChew ER |
Methylphenidate hydrochloride |
Extended-release chewable tablet |
Once daily |
Chewable solid dosage form |
| Methylphenidate ER capsules |
Methylphenidate hydrochloride |
Extended-release capsule |
Once daily |
Sprinkle or capsule-based administration, depending on product |
The closest direct competitive set is Quillivant XR and other liquid methylphenidate products. Dyanavel XR competes for the same pediatric liquid-dosage need but uses amphetamine rather than methylphenidate.
What generic entry risks exist?
Generic entry could target the active ingredient, release profile, concentration, or dosage form. The most likely pathways are:
- An ANDA for an extended-release oral suspension.
- A 505(b)(2) application with a modified excipient or device system.
- A product using a different polymer or particle-engineering approach.
- A generic with a substituted flavor or preservative system.
- An authorized generic supplied under a brand-linked agreement.
The key technical barriers are bioequivalence, in vitro release matching, dose uniformity throughout bottle life, physical stability, microbial robustness, and acceptable pharmacokinetic variability. A generic may avoid direct infringement by changing the suspension polymer, preservative, flavor, or particle coating while maintaining the same labeled concentration.
What commercial opportunities exist for excipient suppliers?
Which excipient platforms have the strongest opportunity?
Excipient suppliers can pursue several product-development positions:
- Pediatric taste-masking systems. The highest-value platform would mask methylphenidate without slowing gastrointestinal release beyond the reference profile.
- Low-viscosity suspension systems. These can improve syringe filling and caregiver dosing while preserving sedimentation control.
- Preservative-efficient systems. A formulation that reduces sodium benzoate while maintaining antimicrobial protection has potential for lifecycle management.
- Ready-to-use suspension platforms. These can shorten development time for other stimulant liquids and pediatric medicines.
- Unit-dose and closed-container systems. Packaging can reduce contamination and redispersion concerns.
- Excipient-device combinations. A formulation paired with a low-residual-volume oral syringe can improve delivered-dose accuracy.
The most defensible commercial position would combine excipient composition claims with process parameters and performance claims. A formulation patent limited to a common sweetener or buffer is unlikely to create a durable barrier.
Can reformulation support a premium lifecycle strategy?
Yes. A reformulated product could target:
- Better taste.
- Lower viscosity.
- Smaller bottle volume.
- Longer in-use stability.
- Lower preservative concentration.
- Unit-dose convenience.
- Improved adherence packaging.
- A new concentration that reduces administration volume.
- A dispenser that minimizes measurement error.
The regulatory route depends on the change. A modified excipient system may require comparative pharmacokinetic studies, stability data, new microbiological data, and potentially clinical bridging. A change that materially affects release could require a more extensive clinical package.
What is the revenue and licensing opportunity?
RELEXXII participates in the U.S. branded ADHD market, where liquid formulations are commercially valuable despite representing a narrower segment than tablets and capsules. Public company filings generally do not provide a separately reported RELEXXII revenue line, so product-specific revenue exposure cannot be determined from consolidated disclosures alone.
Licensing opportunities are most plausible in four areas:
- Pediatric liquid formulation technology.
- Taste masking and particle coating.
- Oral dosing devices.
- Contract manufacturing for controlled-substance suspensions.
Controlled-substance handling, DEA compliance, serialization, diversion controls, and specialized manufacturing capacity increase the value of an experienced commercial partner. A licensing deal would likely prioritize reliable supply and regulatory execution over a broad excipient portfolio.
How strong is the RELEXXII patent estate?
The patent estate should be rated as moderate if protection relies primarily on formulation and delivery claims rather than composition-of-matter protection for methylphenidate. Methylphenidate is an established active ingredient, so commercial durability depends on:
- Narrowness and validity of extended-release suspension claims.
- Whether claims cover the specific polymer and particle system.
- The availability of noninfringing excipient substitutions.
- Orange Book listing status.
- Remaining patent term.
- Any Paragraph IV litigation or settlement restrictions.
- Manufacturing know-how that is difficult to replicate but not necessarily patent-blocking.
The strongest claims would cover a coordinated set of measurable characteristics, such as particle size, viscosity, redispersion time, dissolution profile, and pharmacokinetic exposure. The weakest claims would cover routine excipients without a demonstrated technical effect.
Key Takeaways
- RELEXXII is a once-daily methylphenidate extended-release oral suspension with value concentrated in pediatric liquid dosing.
- The main excipient opportunities are taste masking, rapid redispersion, lower viscosity, preservative optimization, and improved dose delivery.
- Quillivant XR is the closest direct liquid methylphenidate competitor; Dyanavel XR competes as a liquid amphetamine product.
- Biosimilar risk does not apply because RELEXXII is a small-molecule drug.
- Generic risk is driven by ANDA and Paragraph IV pathways, formulation design-arounds, and the remaining Orange Book patent term.
- A strong lifecycle strategy would combine an improved excipient system with packaging or dosing-device protection.
- Product-specific revenue is not separately disclosed in public filings.
- Excipient suppliers with pediatric taste-masking, suspension, and device platforms have the clearest licensing opportunity.
FAQs
Can RELEXXII be reformulated with a different preservative?
Yes, but the revised formulation would require microbiological effectiveness, stability, compatibility, and regulatory bridging data. A preservative change can also affect taste, pH, and container-closure requirements.
Is a sugar-free RELEXXII formulation commercially feasible?
Yes. The labeled formulation already uses a non-sugar sweetening approach. A new sweetener system would need to preserve palatability, chemical stability, suspension performance, and pediatric tolerability.
Could a generic RELEXXII use different excipients?
Usually yes, provided the generic demonstrates pharmaceutical equivalence and bioequivalence and does not infringe enforceable listed patents. The generic may use a different flavor, buffer, polymer, or preservative system.
Does the oral syringe create separate intellectual-property value?
It can. A calibrated syringe, bottle adapter, low-residual-volume structure, or dose-locking feature may support device claims or trade-secret protection, although device protection alone may not block a competing formulation.
Are excipient patents enough to delay generic launch?
They can delay approval if properly listed, valid, enforceable, and infringed. Their practical value depends on claim scope, Orange Book status, litigation, and whether a generic can redesign the suspension without changing the required pharmacokinetic and pharmaceutical performance.
References
-
U.S. Food and Drug Administration. (n.d.). RELEXXII (methylphenidate hydrochloride) extended-release oral suspension prescribing information.
-
National Library of Medicine. (n.d.). DailyMed: RELEXXII methylphenidate hydrochloride extended-release oral suspension label.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
-
U.S. Food and Drug Administration. (n.d.). Hatch-Waxman Amendments and abbreviated new drug application patent certifications.
